Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000541011 | SCV000628725 | benign | Neurofibromatosis, type 1 | 2024-11-11 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002314941 | SCV000663212 | uncertain significance | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2023-06-20 | criteria provided, single submitter | clinical testing | The p.E2210K variant (also known as c.6628G>A), located in coding exon 43 of the NF1 gene, results from a G to A substitution at nucleotide position 6628. The glutamic acid at codon 2210 is replaced by lysine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Genome- |
RCV000541011 | SCV002560986 | uncertain significance | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV005018912 | SCV005639940 | uncertain significance | Neurofibromatosis, familial spinal; Juvenile myelomonocytic leukemia; Neurofibromatosis, type 1; Neurofibromatosis-Noonan syndrome; Café-au-lait macules with pulmonary stenosis | 2024-05-21 | criteria provided, single submitter | clinical testing |